TPO and aplastic anemia: Romiplostim N01 (QL0911) is a novel thrombopoietin receptor agonist (TPO-RA) ; however, clinical data regarding its efficacy and safety in patients with refractory aplastic anemia (AA) who have failed multiple prior lines of therapy are limited.